European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
No Result
View All Result
Home < INDUSTRIES Health

AbbVie Receives European Commission Approval of VENCLYXTO® (venetoclax) in Combination with a Hypomethylating Agent for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

by Alex Weber
May 26, 2021
A A
Share on LinkedinShare on Twitter

— VENCLYXTO® (venetoclax) in combination with a hypomethylating agent is a new regimen approved by the European Commission (EC) for patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy [1]
— Approval is based on data from AbbVie’s clinical trial program for VENCLYXTO, including the Phase 3 VIALE-A trial, which showed patients treated with VENCLYXTO in combination with azacitidine demonstrated improvements in overall survival versus patients treated with placebo in combination with azacitidine [2]
— Approval is also based on results of the Phase 1b M14-358 trial which showed patients treated with VENCLYXTO in combination with azacitidine or decitabine achieved high remission rates [3]

NORTH CHICAGO, Ill., May 25, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) announced today that the European Commission (EC) has approved VENCLYXTO® (venetoclax) in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.1 The approval is valid in all 27 member states of the EU, as well as Iceland, Liechtenstein, and Norway.

“VENCLYXTO has proven incremental overall survival in treating newly diagnosed AML in patients who are ineligible for intensive chemotherapy when treated with VENCLYXTO plus azacitidine compared to those treated with azacitidine alone,” said Mohamed Zaki, M.D., Ph.D., vice president and head, global oncology development, AbbVie. “We look forward to bringing VENCLYXTO to more AML patients who can potentially benefit from this important new treatment option in EU countries.”

 This is the third extension of indications for VENCLYXTO, a first-in-class B-cell lymphoma-2 (BCL-2) inhibitor. BCL-2 is a protein that prevents cancer cells from undergoing apoptosis, the process that leads to the natural death or self-destruction of cancer cells.1 

This most recent approval is based on results from the Phase 3 double-blind, placebo-controlled VIALE-A (M15-656) and the Phase 1b open-label, nonrandomized, multicenter M14-358 clinical trials. The VIALE-A trial demonstrated patients who received VENCLYXTO in combination with azacitidine showed statistically significantly greater median overall survival (OS) than patients receiving azacitidine alone (p<0.001).2 The Phase 1b M14-358 trial evaluating venetoclax in combination with hypomethylating agents, azacitidine or decitabine, exhibited an overall safety profile that was generally consistent with the known safety profiles of venetoclax combined with azacitidine and the two medications alone.3 

In the VIALE-A trial, the most frequently reported serious adverse events (AEs) in the VENCLYXTO plus azacitidine arm and placebo plus azacitidine arm were febrile neutropenia, pneumonia, sepsis, and haemorrhage.2 In the M14-358 trial, the most frequently reported serious AEs in patients receiving VENCLYXTO in combination with decitabine were febrile neutropenia, pneumonia, bacteraemia and sepsis.3

“The European Commission approval of venetoclax combination therapy offers a new option for people facing what is often a devastating acute myeloid leukemia diagnosis,” said Zack Pemberton-Whiteley, Chair of the Acute Leukemia Advocates Network. “This approval represents an important advancement for the treatment of AML and offers an option for those who are ineligible for intensive chemotherapy.”

In April 2021, AbbVie announced that the European Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion for the Marketing Authorization Application for VENCLYXTO in combination with hypomethylating agents for the treatment of patients with newly diagnosed AML who are ineligible for intensive chemotherapy.

VENCLYXTO is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. 

Tags: < Innovation

Related Industries

Health

Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio

January 25, 2023
Health


Philips and Masimo expand partnership to improve telehealth for patients and clinicians around the world

January 19, 2023
Health

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

January 10, 2023
Health

AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline

January 10, 2023
Health

Boehringer Ingelheim announces appointments to Board of Managing Directors

December 21, 2022
Health

Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology

December 20, 2022

Barclays appoints new co-heads of Investment Banking

January 25, 2023

...

ams OSRAM releases industry leading 0.5Mpixel global shutter CMOS image sensors to save space and power in wearable and mobile devices

January 7, 2023

...

Infineon and Resonac announce the expansion of their cooperation and a new multi-year agreement for delivery of silicon carbide (SiC) materials

January 13, 2023

...

Bosch agreed to acquire roughly 12 percent shares in Husqvarna in total

January 28, 2023

...

Lufthansa submits offer to acquire a stake in ITA

January 19, 2023

...

A. P. Moller – Maersk completes acquisition of project logistics specialist Martin Bencher Group

January 3, 2023

...

Airbus and VDL Group join forces to produce an airborne laser communication terminal

January 11, 2023

...

Das neue ZF-Vorstandsteam (von links nach rechts): Michael Frick, Dr. Martin Fischer, Vorstandsvorsitzender Dr. Holger Klein, Dr. Peter Laier, Sabine Jaskula und Stephan von Schuckmann.
//
ZF’s newly formed Board of Management team (from left to right): Michael Frick, Dr. Martin Fischer, CEO Dr. Holger Klein, Dr. Peter Laier, Sabine Jaskula and Stephan von Schuckmann.

ZF Kicks Off 2023 With New Executive Management Team

January 13, 2023

...

Interview with Jaime Argüelles, CEO of Duro Felguera

January 25, 2023

...

HOLCIM ACQUIRES NICEM

January 11, 2023

...

Asia Pacific Business Asia Pacific Business Asia Pacific Business

EUROPEAN BUSINESS is a premier source of corporate news, business information and insights across broad spectrum of industries in Europe and worldwide.  We are one of the members of the Business World Network.

RESOURCES

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor # european-biz.com

PARTNERSHIP:     partnership # european-biz.com

HUMAN RESOURCE:     hr # european-biz.com

* (replace # with @)

  • Official Site

Copyright © EUROPEAN-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © EUROPEAN-BIZ.COM All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist